VRNA Stock Cash Flow Statements

Verona Pharma plc Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Verona Pharma plc Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31

cash flows from operating activities:
net income:	11,921,000	-16,319,000	-33,827,000	-42,962,000	-14,132,000	-14,687,000	-8,807,000	-16,743,000	-10,451,000	-15,647,000	-17,766,000	-24,837,000	-23,262,000	11,051,000	-22,068,000	-21,290,000
adjustments to reconcile net income to net cash from operating activities:
foreign exchange (gain)/loss	-1,097,000	-470,000			-1,206,000	1,012,000	-740,000	-932,000
amortization of debt issuance costs	692,000	654,000
accretion of ripsa	0	1,654,000	3,893,000
accretion of redemption premium on debt			0	0	22,000	33,000	33,000	18,000	14,000	31,000	32,000	31,000	31,000	31,000	32,000	31,000
loss on extinguishment of debt	0	407,000	0	0
share-based compensation	34,814,000	37,477,000	13,738,000	7,654,000	4,569,000	5,079,000	5,074,000	4,290,000	4,504,000	2,816,000	3,053,000	3,748,000	4,187,000	4,938,000	7,450,000	8,850,000
depreciation	293,000	295,000	259,000	266,000		155,000	157,000	157,000
changes in operating assets and liabilities:
accounts receivable	-20,699,000	-30,663,000	-24,592,000
prepaid expenses	-115,000	-3,744,000	391,000	-2,531,000	-285,000	-2,438,000	667,000	938,000	856,000	1,376,000	-3,485,000	2,791,000	2,635,000	3,145,000	-2,570,000	-2,709,000
tax incentive receivable			-556,000	-1,611,000		310,000	1,933,000	-2,313,000		-2,652,000	-4,883,000	-1,578,000
inventory	-770,000	-5,531,000	-3,906,000
other current assets	9,408,000	-9,980,000	708,000	-867,000	3,037,000	-244,000	-3,378,000	1,362,000	-311,000	-871,000	319,000	-462,000	-1,396,000	1,653,000	-836,000	236,000
accounts payable	-5,643,000	-2,189,000	4,435,000	2,679,000	2,573,000	-1,670,000	-4,744,000	4,327,000	-5,104,000	-1,362,000	1,300,000	-1,980,000	10,035,000	-25,000	-507,000	363,000
accrued expenses	10,993,000	16,113,000	-1,921,000	3,125,000	-3,996,000	-70,000	-10,236,000	3,951,000	-9,226,000	-5,625,000	-274,000	6,621,000	-4,206,000	9,270,000	8,674,000	-2,349,000
royalties payable	-1,399,000	3,387,000	931,000
operating lease liabilities	-193,000	-228,000	-262,000	-208,000
income taxes	-9,214,000	-240,000	7,878,000	0	-83,000	-15,000
other current liabilities	-304,000	-2,184,000	2,018,000	-356,000	19,000	-28,000	-65,000	-886,000	1,319,000	-10,000	-48,000	-65,000	-79,000
net cash provided by/(used in) operating activities
cash flows from investing activities:
purchases of furniture and equipment	0	-535,000	-535,000	0					0	0			-1,000
net cash from investing activities	0	-535,000	-535,000	0					0	0
cash flows from financing activities:
proceeds from term loans	0	122,500,000	0	0
proceeds from ripsa			0	0
payment of debt issuance costs			0	-4,612,000
repurchase of ripsa	0	-109,921,000
repayment of 2023 term loans				0
payments of withholding taxes from share-based awards	0	-4,287,000	-4,263,000	-6,143,000					-2,341,000	-900,000	-689,000	-793,000	-901,000	-2,167,000
proceeds from exercise of share options	4,943,000	5,165,000	924,000	3,668,000	-3,000	48,000	77,000	1,827,000	1,001,000
net cash from financing activities			94,157,000	-7,087,000	24,012,000						-689,000	-726,000
effect of exchange rate changes on cash and cash equivalents	1,097,000	297,000	-1,069,000	1,183,000	796,000	-682,000	499,000	685,000	1,250,000	-1,333,000	-1,019,000	-378,000	58,000	-485,000	41,000	163,000
net change in cash and cash equivalents	36,601,000	1,658,000	63,717,000	-68,559,000	14,406,000	-13,361,000	-20,688,000	63,588,000	-3,874,000	120,191,000	-21,254,000	-15,616,000	-18,167,000
cash and cash equivalents at beginning of the period	0	399,757,000		0		0	0	227,827,000		0	0	148,380,000		0	0	187,986,000
cash and cash equivalents at end of the period	36,601,000	401,415,000		-68,559,000		-13,361,000	-20,688,000	291,415,000		120,191,000	-21,254,000	132,764,000		20,512,000	-23,563,000	169,598,000
supplemental disclosure of cash flow information:
income taxes paid			393,000		30,000	0			30,000	89,000	0	1,000
interest paid	6,246,000	10,151,000	3,878,000	4,431,000	778,000	543,000	441,000	244,000	158,000	75,000	62,000	53,000	53,000	53,000	54,000	55,000
net cash from operating activities		-11,561,000	-28,836,000	-62,655,000	-10,402,000	-12,727,000	-21,311,000	-5,782,000	-7,738,000	-18,095,000	-19,517,000	-14,512,000	-17,323,000	22,825,000	-20,205,000	-18,551,000
capex		-535,000	-535,000	0	0	0	0	0	0	0	0	0	-1,000	0	0	0
free cash flows		-12,096,000	-29,371,000	-62,655,000	-10,402,000	-12,727,000	-21,311,000	-5,782,000	-7,738,000	-18,095,000	-19,517,000	-14,512,000	-17,324,000	22,825,000	-20,205,000	-18,551,000
net cash provided by/(used in) financing activities		13,457,000					124,000	68,685,000	2,614,000
operating activities:
foreign exchange loss/											2,137,000	1,119,000
proceeds from issuance of ordinary shares					0	0	47,000	56,862,000	67,000
payment of offering costs in connection with the issuance of ordinary shares									49,000
proceeds from 2023 term loan, net of repayment of oxford term loan and debt issuance costs incurred
repayment of term loans
svb term loan repayment costs
cash and cash equivalents at beginning of the year
cash and cash equivalents at end of the year
foreign exchange gain															-31,000	-155,000
amortization of debt issue costs									13,000	23,000	21,000	23,000	22,000	22,000	51,000	19,000
other non-cash items						15,000	15,000	73,000
license agreement obligations
depreciation and amortization									151,000	157,000	165,000	163,000	162,000	162,000	152,000	153,000
tax incentive receivables
proceeds from oxford term loan
repayment of svb term loan
right-of-use asset
lease liabilities						-179,000	-140,000	-165,000		197,000	-164,000	-174,000	-550,000	-216,000	603,000	-210,000
proceeds from draw under the oxford term loan						0	0	9,996,000
taxes payable								141,000	-2,000	-26,000	76,000	88,000	-304,000
fair value movement on warrants													-2,000	-40,000	-2,711,000	507,000
equity interest recognized as revenue
right-of-use assets
proceeds from issuance of oxford term loan
oxford term loan issuance costs
foreign exchange loss
equity interest receivable
proceeds from at-the-market sales agreement										0	0	67,000		350,000
deferred revenue
impairment of right-of-use asset
sale of short-term investments
net cash (used in)/provided by investing activities													-1,000
proceeds from issuance of term loan
term loan issuance costs
net cash (used in)/provided by financing activities													-901,000
equity interest
tax and tax incentive receivables															-3,836,000	-2,012,000
non-current assets
other liabilities															167,000	15,000
net decrease in cash and cash equivalents
net increase in cash and cash equivalents																-18,388,000
foreign exchange (gain) / loss
cash flows from investing activities
purchases of short-term investments
cash flows from financing activities
proceeds from the issuance of term loan

We provide you with 20 years of cash flow statements for Verona Pharma plc stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Verona Pharma plc stock. Explore the full financial landscape of Verona Pharma plc stock with our expertly curated income statements.

The information provided in this report about Verona Pharma plc stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.